Wired For Addiction™ is an international DNA company that looks at genetic variants linked to addiction and mood disorders. Utilizing their patent-pending custom genetic panel, they identify, isolate, and measure 85 biomarkers highly correlated to substance use disorders and mental health conditions.
Through Wired For Addiction’s remote sample collection process, patients are able to provide their specimen from the comfort of their home or treatment facility, thereby eliminating geographical and logistical barriers to care. Once the samples have been sent to the Wired For Addiction™ lab(s) via the prepaid postage contained in the kits, their DNA, neurotransmitters, and hormones are analyzed, interpreted, and configured into their unique Biomarker Evaluation Report. This report itemizes the results of their specimen, the clinical correlation associated with the findings, and the prescribed treatment protocol, if so desired.
In 2021, Wired For Addiction™ was contacted by a 42 year old, Caucasian, male who reported various addictions throughout his life with a current gambling and alcohol addiction jeopardizing his employment and financial stability. He testified that he had been able to stop drinking for periods of time but relapsed after months of abstinence. The gambling, however, he said was uncontrollable and did not know how or where to get treatment for his addiction.
Wired For Addiction™ shipped the patient their patent-pending custom genetic test kit to his home where he collected his samples according to the instructions included in the kit. The test kit was sent back to the lab utilizing the prepaid shipping label in the kit and the results were analyzed and interpreted by the assigned Wired For Addition™ clinician who went on to create the patient’s Biomarker Evaluation Report and treatment protocol.
The assigned Wired For Addiction™ clinician and the patient shared a virtual telehealth appointment to discuss the genetic findings, their correlation to his symptomatic experience, and the prescribed treatment protocol. He agreed to the Wired For Addiction™ treatment plan, the prescriptions were sent electronically to be filled, he agreed to join a 12-Step Support Group, and the care commenced.
After following the prescribed treatment protocol for 6 months and maintaining bi-weekly telehealth visits to ensure adherence to the protocol, the patient underwent a retest to evaluate the efficacy of his genetic-guided biochemical pathway support. As expected, the patient not only experienced improved sleep, focus, emotional regulation, reduced cravings, fewer obsessive thoughts -- his objective biomarkers supported those symptomatic improvements.
Eight of the 11 neurotransmitters and three of the four hormones measured in Wired For Addiction’s custom genetic panel were optimized. The 24 heterozygous and homozygous single nucleotide polymorphisms revealed in the panel such as Catechol-O-Methyltransferase, Glutamate decarboxylase 1, and Monoamine oxidase B were supported leading to optimized biochemical pathways thereby reducing the correlated aberrant behaviors.
Process addictions such as gambling are considered more difficult to treat because the thought of engaging in the activity is, in part, responsible for the addiction itself; instead of ingesting a substance, the addiction is in the process of participating in an activity. Because of this noncomprehensive view of process addictions, few resources are made available to sufferers. Wired For Addiction™ is effective in diagnosing and treating process addictions because the same biochemical pathways are engaged in a process addiction as they are in substance use disorders. Wired For Addictions’ patent-pending genetic panel identifies, isolates, and measures specific biomarkers requiring optimization for mental health. By determining the precise biochemical pathway(s) requiring support and the level to which support is required is what yields measurable and experiential improvement.
Comments